Background: The continuous search for new lead compounds as viable inhibitors of specific enzymes linked to carbohydrate metabolism has intensified. Cyperus esculentus L. is one of the therapeutically implicated botanicals against several degenerative diseases including diabetes mellitus. Materials and Methods: This study evaluated the antioxidant and mechanism(s) of inhibitory potential of aqueous extract of C. esculentus on α-amylase and α-glucosidase in vitro. The extract was investigated for its radical scavenging and hypoglycaemic potentials using standard experimental procedures. Lineweaver-Burke plot was used to predict the manner in which the enzymes were inhibited. Results: The data obtained revealed that the extract moderately and potently inhibited the specific activities of α-amylase and α-glucosidase, respectively. The inhibition was concentration-related with respective IC50 values of 5.19 and 0.78 mg/mL relative to that of the control (3.72 and 3.55 mg/mL). The extract also significantly scavenged free radicals and the effects elicited could be ascribed to its phytoconstituents.
Introduction
Tiger nut or Cyperus esculentus L. (Cyperaceae) is widely cultivated and used as dietary supplement in the Arabian Peninsula, Spain, east Africa, and many West African countries including Nigeria (Abaejoh et al., 2006) . It is an erect fibrous-rooted perennial plant, 1 to 3 ft tall and reproduces by seeds and rhizomes (Belewu and Abodunrin, 2006) . The tubers of C. esculentus (CE) are edible with characteristic sweet nutty flavor. In Nigeria, the fresh tuber is either roasted, baked, dried, eaten raw or prepared as 'kunnu' (Oladele and Aina, 2007) . Its fat composition is similar to that of olive plant with 72% unsaturated (oleic acid and linoleic acid) and 28% saturated (palmitic acid and stearic acid) fatty acids (Zhang et al., 1996) . CE is also rich in phosphorus and potassium (Belewu and Belewu, 2007) . Extracts of CE have been used as anti-cancer, anti-microbial, anti-diarrhoea, anti-flatulence as well as in the treatment of anaemia, urinary tract infections and hypercholesterolemia (Chevallier, 1996 Diabetes mellitus (DM) is a metabolic disorder with significant impact on the well-being and quality of life of humans. The disease is significantly emerging as one of the greatest heath challenges to human (Vasim et al., 2012) . The global incidence of DM revealed an estimated 171 million people as victims of the disease in 2000, and it has been projected that the prevalence will increase to 366 million by 2030 if no practicable and sustainable intervention is adopted (Wild et al., 2004) . A more recent report on its global prevalence has predicted an increase in this figure, pegging it at well above 438 million by 2030 (Colagiuri, 2010) . With this prediction, someone dies from its complications every 10 sec and 1 in every 5 persons may be gravely affected. In sub-Saharan Africa, DM is also an important emerging disease presenting South Africa as the most affected with a prevalence of 8.3% and closely followed by Nigeria (4.5%) (IDF, 2014) . This exponential increase in the prevalence of DM may be either due to changes in diet (highly refined diets), aging and lifestyle of the people (reduced physical activity, urbanization etc.) or ravaging effect of free radicals (Wild et al., 2004) . While orthodox interventions have been embraced and have proved to be effective in the treatment of DM, affordability, sensitivity and side effects have undermined their uses (Campbell et al., 1996) . Interestingly, the management of diabetes via natural sources (as probable alternative) has been achieved either by inhibiting free radical events or/and inhibition of key enzymes ( -amylase and -glucosidase) involved in starch digestion (Sabiu and Ashafa, 2016) . The incidence of DM is closely linked with increased free radical formation and malfunctioning antioxidant defense systems (Maritim et al., 2003) .
Additionally, the occurrence of oxidative stress is a crucial event in both the diabetogenic process and its secondary complications (Lipinski, 2001) . In light of these, antioxidant-rich sources could serve a good dietary intervention in the management of the disease. Besides being rich in antioxidant vitamins and minerals (Belewu and Belewu, 2007) and its flour routinely recommended as one of the dietary control options for the diabetic patients, extracts from CE have been used to treat and manage diabetes (Salwa et al., 2010) . However, there is information gap on the tentative mechanism for the use of the extract to treat such debilitating ailment. This study, therefore investigated the appropriateness of CE extract as a dietary alternative for the management of DM by evaluating its -amylase and -glucosidase inhibitory activities. The antioxidant property of CEE was also determined.
Materials and Methods

Chemicals and reagents
Acarbose was procured from Bayer Medical Co., Germany. While porcine pancreatic α-amylase, rat intestine acetone powder (RIAP), p-nitrophenyl-α-D-glucopyranoside (pNPG), sodium dodecyl sulphate (SDS), silymarin and 1,1-diphenyl-2-picryl-hydrazyl (DPPH) were purchased from Sigma Chemical Co., St. Louis, Missouri, USA, soluble starch and dinitrosalicylic acid (DNS) were products of J. T. Baker Inc., Phillipsburg, USA. Water used was glass-distilled and other chemicals were of analytical grade.
Plant collection, extract preparation and phytochemicals quantification
Fresh tubers of CE were collected from the Ilorin metropolis Emir's market, Nigeria and were authenticated at Plant Sciences Department, University of Ilorin, Ilorin, Nigeria. A voucher specimen (UIH001/21781) was subsequently deposited at the Herbarium of the University. The tubers were rinsed under running tap, oven-dried (37 
In vitro antioxidant assays DPPH radical inhibition
The DPPH radical scavenging effect of CEE was evaluated as previously described (Turkoglu et al., 2007) . In brief, 1 mL of varying methanolic concentrations (0.2-1.0 mg/mL) of the CEE or silymarin (standard) was added to 1 mL of 0.2 mM methanolic solution of DPPH. Similarly, sterile distilled water (1 mL) was mixed with an aliquot (1 mL) of 0.2 mM methanolic DPPH and used as control. Following an incubation period of 30 min at room temperature in each case, the absorbance was read against blank at 516 nm using a spectrophotometer (Beckman, DU 7400, USA). The inhibitory ability (I%) of CEE on DPPH radical was estimated as: I% = [(Acontrol -Atest)/Acontrol] × 100, where Acontrol = absorbance of the control, Atest = absorbance of the test sample. Thereafter, the concentration of CEE producing 50% inhibitory (IC50) effect on the DPPH radical was calculated from a standard curve.
Hydrogen peroxide inhibition
The adapted procedure of Ruch et al. (1989) was used in this assay. In brief, 0.6 mL H2O2 (40 mM) was mixed with 3.4 mL of phosphate buffered (pH 7.4) solution of 0.2-1.0 mg/mL concentrations of either CEE or silymarin and incubated (25 0 C, 10 min). The extract was replaced with distilled water for the control sample and the absorbance in each case was spectrophotometrically read (230 nm). The H2O2 inhibitory potential of CEE was thereafter calculated using: % H2O2 scavenged = [Acontrol -(Atest -Asample)/Acontrol] × 100, Acontrol is the absorbance of the control. Atest and Asample represent the absorbance of the mixture with the extract and that of the extract alone, respectively. The IC50 value was thereafter estimated from the calibration curve.
Hydroxyl radical (OH*) inhibition
The OH* inhibitory effect of CEE was determined as earlier reported (Smirnoff and Cumbes, 1996) . In brief, 2 mL of the extract or silymarin (at 0.2-1.0 mg/mL) were mixed with 0.6 mL of ferrous sulfate (8 mM), 0.5 mL of H2O2 (20 mM) and 2 mL of salicylic acid (3 mM). After 30 min of incubation (37 o C), distilled water (0.9 mL) was added and the resulting mixture centrifuged (Beckman and Hirsch, Burlington, IO, USA) at 4,472 g for 10 min. For the control, sterile distilled water was used. The absorbance in each case was read at 510 nm and the IC50 value was calculated subsequent to determination of inhibitory capacity of CEE against OH* using the expression: % hydroxyl radical scavenged = [Acontrol -(Atest -Asample)/Acontrol] × 100, Acontrol, Atest and Asample represent the absorbance of the control, mixture with the extract and that of the extract alone, respectively.
Lipid peroxidation assay
The capability of CEE to halt generation of lipid peroxide in an egg yolk homogenate was adapted in this assay (Oyedemi et al., 2012) . Exactly 0.5 mL (10% in distilled water) of the yolk homogenate was mixed with different concentrations (0.1 mL) of either CEE or silymarin in different sets of tubes. Following making the mixture up to 1 mL with distilled water, 0.07 M Ferrous sulphate solution (0.05 mL) was introduced and incubated (60°C, 30 min) to enhance peroxidation. This was followed by the addition of 0.05 mL of 20% trichloroacetic acid and 1.5 mL each of acetic acid (20%) and 0.8% thiobarbituric acid (in 1.1 % w/v SDS). The resulting solution was boiled (100°C, 1 h). After cooling (25°C), n-butanol (5.0 mL) was introduced and centrifuged (3000 rpm, 10 min). While sterile distilled water replaced the extract as blank, the absorbance of the supernatant was then spectrophotometrically (Beckman, DU 7400, USA) read (532 nm).
In vitro antidiabetic assays Kinetics of α-amylase inhibition
This was achieved following reported methods (Elsnoussi et al., 2012; Sabiu et al., 2016b) . Briefly, known concentrations (0.25-10.0 mg/mL) of the extract or acarbose (standard) were prepared and 500 µL of each was mixed with 500 µL of 0.02 M sodium phosphate buffer (pH 6.9) containing 0.5 mg/mL of ice cold porcine pancreatic α-amylase solution in test tubes. The reaction mixtures were then incubated (25ºC, 10 min). Subsequently, 500 µL of 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9) was introduced into each tube. The mixtures were further incubated (25ºC, 10 min) prior to 1.0 mL addition of DNS colour reagent to halt the reaction. The tubes were then heated (100 ºC, 5 min), completely cooled (25 ºC) and the diluted (sterile distilled water, 15 mL) prior to absorbance reading (540 nm) (Beckman, DU 7400, USA). The control contained the buffer (500 µL) instead of the extract. The experiments were conducted in triplicate and the α-amylase inhibitory potential of CEE was then calculated and expressed as percentage:
where ∆Aextract and ∆Acontrol are the respective changes in absorbance of the extract sample and control. The IC50 of CEE against α-amylase activity was thereafter calculated from a standard calibration plot.
Subsequently, 100 µL of either the extract (at it IC50) or sodium phosphate buffer (pH 6.9, 0.02 M) was preincubated (25ºC, 10 min) with α-amylase solution (100 μL) in two sets of test tubes. Following this, varying concentrations (0.3-5.0 mg/mL) of starch (substrate (S)) was added to both sets of mixtures to initiate the reaction. Finally, the resulting mixture in each case was further treated with DNS (100 μL), boiled (100 ºC, 5 min) and allowed to proceed as highlighted above. The released reducing sugar was then spectrophotometrically (Beckman, DU 7400, USA) estimated from maltose standard curve. The values obtained were expressed as reaction rates (v). Using Lineweaver-Burk double reciprocal plot (Lineweaver and Burk, 1934) , the kinetic indices (Km and Vmax values) and the tentative mechanism of inhibitory effect of CEE on the activity of α-amylase was predicted.
Kinetics of α-glucosidase inhibition
The adapted method of Oki et al. (1999) was used to prepare α-glucosidase solution from RIAP. Briefly, the RIAP (25 mg/mL) was homogenized (ice-cold 50 mM phosphate buffer), centrifuged (6000 × g, 15 min) and the resulting clear supernatant was used as the enzyme solution for determination of the specific activity of α-glucosidase. However, for the inhibitory effect of the extract on the activity of the enzyme, the procedure of Elsnoussi et al. (2012) was used. Briefly, different concentration (0.25-10.0 mg/mL) of the extract or acarbose were prepared and 50 µL from each stock solution was mixed with 100 µL of 0.1 M phosphate buffer (pH 6.9) containing 1.0 M of α-glucosidase solution and incubated in 96-well plates at 25ºC for 10 min. Following this, 50 µL of 5 mM pNPG solution in 0.1 M phosphate buffer (pH 6.9) was added to each well and the reaction mixtures were further incubated at 25ºC for 5 min. The absorbance in each case was read at 405 nm using a micro-plate reader (Thermomax, USA) and the values compared with a control which contained 50 µL of the buffer instead of the extract. The assay was triplicated and the inhibitory effect of the extract on the activity of α-glucosidase was calculated. Using standard calibration curve, the concentration of the extract causing 50% inhibition (IC50) of α-glucosidase activity was extrapolated.
To further determine the inhibitory kinetics of the extract against the specific activity of α-glucosidase, 50 μL of the extract (at its IC50) was pre-incubated (25°C, 10 min) with 100 μL of α-glucosidase solution in a set of tubes. In separate set of tubes, the α-glucosidase solution was similarly pre-incubated with phosphate buffer (pH 6.9, 50 μL). Subsequently, 50 µL of pNPG (0.63 -2.0 mg/mL) was added to both sets of mixtures to initiate the reaction. The reaction mixture was then incubated (25°C, 10 min), and 500 µL of Na2CO3 was added to stop the reaction. The released sugar in each case was colorimetrically estimated using a p-nitrophenol calibration curve. Rates of reaction (v) were then estimated and Lineweaver-Burk double reciprocal plot was used to predict the nature of inhibition of the enzyme by CEE.
Data computation
Results were subjected to one-way analysis of variance (ANOVA) using SPSS software package for windows (Version 16, SPSS Inc., Chicago, USA) and expressed as mean ± standard error of mean (SEM) of replicate determinations. Using Duncan's Multiple Range Test, significantly different means was considered at 95% confidence level.
Results
Quantified phytoconstituents and antioxidant activity
Data on the quantified phytoconstituents of the CEE revealed that it is composed of 17.65 ± 0.25, 29.32 ± 0.12, and 10.38 ± 0.25% w/w of alkaloids, saponins and tannins, respectively (Table 1) . The result of the in vitro antioxidant potential of the extract is presented in Table 2 . The extract dose dependently inhibited and scavenged the formed radicals with significant effect exhibited against the DPPH radical judging by the IC50 value (0.25 mg/mL) when compared with silymarin (0.82 mg/mL). Similarly, compared with the standard (silymarin, IC50 0.67 mg/mL), the CEE (IC50 0.27 mg/mL) remarkably scavenged H2O2 radical. For the OH and lipid peroxidized radicals, the extract also displayed significant radical scavenging effect (IC50 0.75 and 0.45 mg/mL, respectively) and competed favorably with silymarin (0.71 and 0.50 mg/mL). The coefficient of determination (R 2 ) values in each case is also presented ( Table 2 ). 
In vitro enzyme kinetics inhibitory potentials
The data obtained with respect to the inhibitory potential of the CEE on the specific activities of α-amylase and α-glucosidase revealing dose-related effect are shown in Table 3 . While the inhibitory effect of the extract against α-amylase was significantly (p<0.05) different from that elicited by acarbose (reference drug) at higher doses (5.0-10.0 mg/mL), the lower doses revealed non-significant (p>0.05) influence. The IC50 values for CEE (5.19 mg/mL) and acarbose (3.72 mg/mL) were also significantly (p<0.05) different (Table 3) . Investigation into the mechanism of action of the CEE on the enzyme revealed that the enzyme was competitively inhibited (Fig. 1) . The respective Km values for the control and CEE were 0.002 and 0.003 mg, while the Vmax was 0.05 μM/min. Contrary to the observation on the α-amylase, the CEE significantly (p<0.05) inhibited the activity of α-glucosidase at the lower (0.25-2.50 mg/mL) and highest (10.0 mg/mL) investigated concentrations, with the highest dose eliciting the best and most prominent effect relative to the control. This was further supported by the lower IC50 value (0.78 mg/mL) for the extract when compared with acarbose (3.55 mg/mL) ( Table 3 ). The kinetics evaluation of the tentative mode of inhibition of α-glucosidase showed that the enzyme was independently inhibited by the extract. The reciprocal plot showed a decrease in both Vmax and Km values for the extract (0.02 μM/min, 0.0006 mg) relative to the control (0.05 μM/min, 0.0015 mg), thereby indicating an uncompetitive mode of inhibition (Fig. 2) . 
Discussion
Of the carbohydrates-metabolizing enzymes, the -glucosidase and -amylase represent the most crucial of the pharmacological targets in the management of DM (Krentz and Bailey, 2005) . These enzymes facilitate hydrolysis of starch to glucose with consequential increase in the systemic concentration of glucose. This increased hyperglycemia may constitute an independent risk factor for the development of microvascular and macrovascular complications of diabetes mellitus which is mediated through oxidative stress (Kim et al., 2000) . Hence, the inhibition of these enzymes activities delays glucose absorption and moderates postprandial blood sugar level (Sabiu and Ashafa, 2016) . As presented in this study, CEE had significant inhibitory effect on the specific activities of -amylase and -glucosidase. Judging by the IC50 values and relative to the standard, it was evident that the extract elicited a stronger inhibition on the activity ofglucosidase than -amylase and this is therapeutically significant in abolishing the adverse effects consistent with the conventional -glucosidase and -amylase inhibitors (Sabiu et al., 2016b) . The competitively inhibited activity of the α-amylase is indicative of a stronger structural resemblance of the major constituent of the extract to the substrate which facilitated its favourable binding on the active site of the enzyme at the expense of the substrate. By effect, the rate of starch hydrolysis to free glucose is either effectively reduced or abolished. Furthermore, the reduced Vmax and Km values for the extract (predicting uncompetitive mode of inhibition on the activity of α-glucosidase) may suggest a higher affinity of the enzyme for CEE than the substrate, thereby strategically modulating further carbohydrate hydrolysis.
The relationship between generation of free radicals and the pathogenesis of DM and its complications has been demonstrated (Wolff, 1993) . In the present study, the extract of CE exhibited significant anti-radical activities as shown by its IC50 values when compared with the reference antioxidant used. The closeness of the R 2 values to 1.0 is not only suggestive of either precision or accurate submissions for all the assays conducted, but also informative of the capability of CEE to stall free radicals chain reactions associated with diabetes complications. Besides being consistent with previous in vitro studies ( Overall, the effects elicited by CEE in this study could be ascribed to its minerals and phytonutrients which are known for their antidiabetic attributes. Besides containing tannins, alkaloids and saponins [whose antidiabetic potentials in aiding regeneration of pancreatic β-cells and inhibition of the specific activities of α-glucosidase and α-amylase have been reported (Kunyanga et al., 2011; Zheng et al., 2011; Madhusudhan and Kirankumar, 2015) ], previous report on the GCMS analysis of CEE also revealed rotundiene (0.87%), taxol (0.32%), camptothecin (1.12%), morphine (1.36%), allicin (1.11%), viblastine (5.24%), isokobosone (5.33%), tubocurrarine (5.43%), capscicine (6.79%), p-cymol (7.34%), vincristine (7.64%) and digoxigenin (8.11%) as its major adaptogenic constituents (Sabiu et al., 2016a) . These compounds have been implicated either as ROS scavengers or hypoglycemic agents (Harikesh et 
Conclusion
The data presented in this study have demonstrated CEE as a tentative novel and potential inhibitor with specific and high affinity for carbohydrate hydrolysing enzymes. This was achieved by competitively and uncompetitively inhibiting α-amylase and α-glucosidase, respectively, thus modulating the rates of carbohydrate metabolism to glucose.
While further clinical trials with CEE may be imperative, effort is underway to completely characterize its implicated antidiabetic constituent(s).
